Jay D. Hatfield, CEO of Infrastructure Capital Advisors, says he's "bullish on financials, but more bullish on investment banks," as he expects not only an M&A boom "because of more reasonable ...
Jay D. Hatfield, CEO of Infrastructure Capital Advisors, said strong net interest margins for banks and "AI upside" for tech are why he's bullish on those companies' stocks. Could AI-assisted program ...
Macy's CEO Tony Spring, who is trying to turn around the company, wants to prove to the public markets that its three-brand ...
Gilead Sciences and LEO Pharma have entered a strategic collaboration to expedite the development and commercialisation of ...
Gilead Sciences Inc. and LEO Pharma have partnered to accelerate the development and commercialization of LEO Pharma’s small ...
Gilead licenses Leo Pharma's oral STAT6 portfolio for inflammatory diseases in $250M upfront deal, potentially worth $1.7B, ...
Gilead Sciences continues its divergence out of its original infectious disease beginnings and into cancer and now, more ...
Gilead Sciences, Inc. (Nasdaq: GILD) and LEO Pharma today announced a strategic partnership to accelerate the development and ...
Hosted on MSN5d
Morgan Stanley Upgrades Gilead Sciences (GILD)Fintel reports that on January 10, 2025, Morgan Stanley upgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from Equal ...
Portfolio Receipts expected to be approximately $2,800 million, at the upper end of guidance rangeExciting development-stage pipeline with ...
The split-up of Galapagos is only the latest shake-up in the company in recent years. Other major events have included the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback